Piper Sandler analyst David Amsellem downgraded Xeris Biopharma (XERS) to Neutral from Overweight with an unchanged price target of $3, post ...
The Piper Sandler (NYSE ... is going to be volatile but the market is backing this stock today. Analyst David Amsellem reiterated his overweight rating of Revance Therapeutics (NASDAQ:RVNC ...
The Commodity Futures Trading Commission said it ordered Piper Sandler to pay a $2 million fine to settle charges against the company's introducing broker for failing to meet recordkeeping ...
Piper Sandler analyst David Amsellem downgraded the rating on Xeris Pharmaceuticals (XERS – Research Report) to a Hold yesterday, setting ...
ANI Pharmaceuticals (NASDAQ:ANIP) traded higher in the premarket trading on Friday after Piper Sandler launched ... company's portfolio mix. Analyst David Amsellem argued that Baudette, ...
Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.
Piper Sandler Companies (NYSE:PIPR) had its earnings report come in. The last time we covered them, we acknowledged that ECM and DCM spurts may be short-lived, which is what happened. However ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
NEW YORK - Piper Sandler Companies (NYSE: PIPR), a prominent investment bank, and BC Partners Credit have announced a strategic alliance aimed at enhancing debt capital market access for financial ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...